RIOX2

Across TCGA pan-cancer cohorts, RIOX2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RIOX2 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RIOX2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RIOX2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

OV, UCEC, and GBM are the cancer types where RIOX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.076	0.844	<.001	48	view →
UCEC	DFS	Median	All	0.968	0.616	.007	16	view →
GBM	DFS	Median	All	0.064	0.257	.014	6	view →
LUSC	DFS	Median	All	1.000	0.363	.010	4	view →
COAD	OS	Median	III,IV	0.168	0.692	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RIOX2–OV (OS)

Open the OV breakdown →